Duchenne muscular dystrophy (DMD) is a serious degenerative muscular disease affecting males. Diagnosis usually occurs in childhood and is confirmed through genetic testing and/or muscle biopsy. Accompanying the disease are several nutrition-related concerns: growth, body composition, energy and protein requirements, constipation, swallowing difficulties, bone health, and complementary medicine. This review article addresses the nutrition aspects of DMD.
EmeryAE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1:19-29.
2.
LetellierGMokMAlbertiC. Effect of glutamine on glucose metabolism in children with Duchenne muscular dystrophy. Clin Nutr. 2013;32(3):386-390.
3.
LiewWKMKangPB. Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord. 2013;6(3):147-160.
4.
PaneMVastaIMessinaS. Feeding problems and weight gain in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2006;10(5-6):231-236.
5.
BushbyKFinkelRBirnkrantDJ. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
6.
BushbyKBourkeJBullockREagleMGibsonMQuinbyJ. The multidisciplinary management of Duchenne muscular dystrophy. Curr Pediatr. 2005;15:292-300.
7.
MoxleyRTPandyaSCiafaloniEFoxDCampbellK. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 25(9):1116-1129.
8.
WilligTNCarlierLLegrandMRiviereHNavarroJ. Nutritional assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 1993;35(12):1074-1082.
9.
AloysiusABornPKinalMDavisTPaneMMercuriE. Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies. Eur J Pediatr Neurol. 2008;12(3):239-245.
10.
MartigneLSeguyDPellegrini. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr. 2010;29(1):60-64.
11.
BushbyKFinkelRBirnkrantDJ. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(3):177-189.
12.
BorrelliOSalviaGManciniV. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol. 2005;100(3):695-702.
13.
WeberTKToporovskiMSTahanSNeufeldCBde MoraisMB. Dietary fiber mixture in pediatric patients with controlled chronic constipation. J Pediatr Gastroenterol Nutr. 2014;58(3):297-302.
14.
NabukeraSRomittiPCampbellK. Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy. J Child Neurol. 2012;27(6):734-740.
15.
GriffithsRDEdwardsRH. A new chart for weight control in Duchenne muscular dystrophy. Arch Dis Child. 1988;63:1256-1258.
16.
SarrazinEHagenMVScharaUAuKVKaindlAM. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2014;18(1):38-44.
17.
NagalBHMortierWElmlingerMWollmannHASchmittKRankeMB. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr. 1999;88(1): 62-65.
18.
WestNAYangMLWeitzenkampDA. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2013;163(6):1759-1763.
19.
Centers for Disease Control and Prevention. Growth charts. http://www.cdc.gov/growthcharts/. Updated September9, 2010. Accessed January 5, 2015.
20.
McDonaldCMAbreschRTCarterGT. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehab. 1995;74(5):S70-S92.
21.
ZatzMOpitzJM. Effects of genetic counseling on Duchenne muscular dystrophy families in Brazil. Am J Med Genet. 2005;15(3):483-490.
22.
EkvallSEkvallVK. Pediatric Nutrition in Chronic Diseases and Developmental Disorders. New York, NY: Oxford University Press; 2005:50.
23.
ten DamKde GrootIJMNoordamC. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen. Neuromuscul Disord. 2012;22(6):500-504.
24.
KinaliMMainMEliahooJ. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2007;11:160-166.
25.
SussmanMD. Advantage of early spinal stabilization and fusion in patients with Duchenne muscular dystrophy. J Pediatr Orthop. 1984;4(5):532-537.
26.
HsuJDQuinlivanR. Scoliosis in Duchenne muscular dystrophy (DMD). Neuromuscul Disord. 2013;23:611-617.
27.
OdaTShimizuNYonenobuKOnoKNabeshimaTKyohS. Longitudinal study of spinal deformity in Duchenne muscular dystrophy. J Pediatr Orthop. 1993;13(4):478-488.
28.
CervellatiSBettiniNMoscatoMGusellaADemaEMaresiR. Surgical treatment of spinal deformities in Duchenne muscular dystrophy: a long term follow-up study. Eur Spine J. 2004;13(5):441-448.
29.
KurzLTMubarakSJSchultzPParkSMLeachJ. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J Pediatr Orthop. 1983;3(3):347-353.
30.
SkalskyAJHanJJAbreschRTShinCSMcDonaldCM. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve. 2009;39(5):647-651.
31.
PessolanoFASuarezAAMesaLDubrovskyARoncoroniAJDe VitoEL. Nutritional assessment of patients with neuromuscular diseases. Am J Phys Med Rehabil. 2003;82(3):182-185.
32.
MokELetellierGCuissetJMDenjeanAGottrandFHankardR. Assessing change in body composition in children with Duchenne muscular dystrophy: anthropometry and bioelectrical impedance analysis versus dual-energy X-ray absorptiometry. Clin Nutr. 2010;29(5):633-638.
33.
PalmieriGMBertoriniTEGriffinJWIgarashiMKarasJG. Assessment of whole body composition with dual energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve. 1996;19(6):777-779.
34.
ElliottSADavidsonZEDaviesPSTrubyH. A bedside measure of body composition in Duchenne muscular dystrophy. Pediatr Neurol. 2015;52(1):82-87.
35.
ZanardiMCTagliabueAOrcesiSBerardinelliAUggettiCPichiecchioA. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr. 2003;57(2):273-278.
36.
TarnopolskyMAMahoneyDJVajsarJ. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62(10):1771-1777.
37.
ElliotSADavidsonZEDaviesPSTrubyH. Predicting resting energy expenditure in boys with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2012;16:631-635.
38.
Gonzalez-BermejoJLofasoFFalaizeL. Resting energy expenditure in Duchenne patients using home mechanical ventilation. Eur Respir J. 2005;25:682-687.
39.
HaugenHAChanLLiF. Indirect calorimetry: a practical guide for clinicians. Nutr Clin Pract. 2007;22(4):377-388.
40.
GallagherDBelmonteDDuerenbergP. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol. 1998;275(2, pt 1):249-258.
41.
HenesSTCummingsDMHicknerRC. Comparison of predictive equations and measured resting energy expenditure among obese youth attending a pediatric healthy weight clinic: one size does not fit all. Nutr Clin Pract. 2013;28(5):617-624.
42.
DavidsonZETrubyH. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet. 2009;22(5):383-393.
43.
Shimizu-FujiwaraMKomakiHNakagawaE. Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain Dev. 2012;34(3):206-212.
44.
HoganSE. Body composition and resting energy expenditure of individuals with Duchenne and Becker muscular dystrophy. Can J Diet Pract Res. 2008;69:208-212.
45.
HankardRGGotrandFTurckDCarpentierARomonMFarriauxJP. Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res. 1996;40:29-33.
46.
BianchiMLBiggarDBushbyKRogolADRutterMMTsengB. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord. 2011;21(4):298-303.
47.
Academy of Nutrition and Dietetics: Behavioral Health Nutrition Dietetic Practice Group and Pediatric Nutrition Practice Group. Pocket Guide to Children with Special Health Care and Nutritional Needs. Chicago, IL: Academy of Nutrition and Dietetics; 2012:38-41.
Lo CascioCMLatshangTDKohlerMFehrTBlochK. Severe metabolic acidosis in adult patients with Duchenne muscular dystrophy. Respiration. 2014;87(6):499-503.
58.
KingWMRuttencutterRNagarajaHN. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68:1607-1613.
59.
KimSCampbellKAFoxDJMatthewsDJValdezR; MD STARnet. Corticosteroid treatments in males with Duchenne muscular dystrophy: treatment duration and time to loss of ambulation [published online November20, 2014]. J Child Neurol.
60.
RicottiVRidoutDAScottE. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84(6):698-705.
61.
AngeliniCPeterleE. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 2012;31(1):9-15.
62.
MayoALCravenBCMcAdamLCBiggarWD. Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord. 2013;22(12):1040-1045.
63.
BootAMEngelsMABoermaGJKrenningEPde Muinck Keizer-SchramaSM. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab. 1997;82(8):2423-2428.
64.
FewtrellMS. Bone densitometry in children assessed by dual X-ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003;(88):795-798.
65.
National Institutes of Health: Office of Dietary Supplements. Dietary supplement fact sheet: calcium–health professional fact sheet. http://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/. Updated November21, 2013. Accessed January 5, 2014.
66.
BiggarWDBachrachLKHendersonRCKalkwarfHPlotkinHWongBL. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord. 2005;15(1):80-85.
67.
Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2010.
68.
U.S. Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference, Release 27. http://www.ars.usda.gov/ba/bhnrc/ndl. Updated September2, 2014. Accessed January 6, 2014.
69.
StraubDA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007;22(3)286-296.
DietzWH. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics. 1998;101(3):518-525.
72.
KrebsNFHimesJHJacobsonD. Assessment of child and adolescent overweight and obesity. Pediatrics. 2007;120:193-228.
73.
KleinmanRE. Pediatric Nutrition Handbook. Elk Grove Village, IL: American Academy of Pediatrics; 2009:759-782.
74.
Freeland-GravesJHNitzkeS. Position of the Academy of Nutrition and Dietetics: total diet approach to healthy eating. J Acad Nutr Diet. 2013;113(2):302-317.
75.
OgataBNHayesD. Position of the Academy of Nutrition and Dietetics: nutrition guidance for healthy children ages 2 to 11 years. J Acad Nutr Diet. 2014;114(8):1257-1276.
76.
RadleyHGDe LucaALynchGSGroundsMD. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell B. 2007;39(3):469-477.
77.
BuetlerTMRenardMOffordEASchneiderHRueggUT. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr. 2002;75(4):749-753.
78.
GordonBSDiazDCDKostekMC. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin Nutr. 2013;32:104-111.
79.
De LucaAPiernoSLiantonioA. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther. 2003;304(1):453-463.
80.
PassaquinACRenardMKayL. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002;12(2):174-182.
81.
Brinkmeyer-LangfordCKornegayJN. Comparative genomics of X-linked muscular dystrophies: the Golden Retriever model. Curr Genomics. 2013:14(5):330-342.
82.
SicinskiPGengYRyder-CookASBarnardEADarlisonMGBarnardPJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989;244(4912):1578-1580.
83.
ChamberlainJSMetzgerJReyesMTownsendDFaulknerJA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007;21(9):2195-2204.
84.
PastoretCSebilleA. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci. 1995;129(2):97-105.
85.
DorchiesOMWagnerSVuadensO. Green tea extract and its major polyphenol (–)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006;290(2):C616-C625.
86.
SpurneyCFRochaCTHenricsonE. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve. 2011;44(2):174-178.
87.
HolecekM. Side effects of long-term glutamine supplementation. JPEN Parenter Enteral Nutr. 2012;37(5):607-616.
88.
HankardRGHammondDHaymondMDarmaunD. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998;43:222-226.
89.
QureshiMMMcClureWCArevaloNL. The dietary supplement protandim decreases plasma osteopontin and improves markers of oxidative stress in muscular dystrophy mdx mice. J Diet Suppl. 2010;7(2):159-178.
90.
MokEViolanteCEDaubrosseC. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006;83(4):823-828.
